Organization (Other)
Duramed Research
ClinicalTrials.gov lists Duramed Research as lead sponsor of 24 trials. It has 2 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Duramed Research: 24 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 3 |
| Pelvic Pain | 3 |
| Urinary Bladder, Overactive | 3 |
| Amenorrhea | 2 |
| Dysmenorrhea | 2 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2009 | 2 |
| 2008 | 5 |
| 2007 | 1 |
| 2006 | 4 |
| 2005 | 10 |
| 2004 | 2 |
| 2003 | 1 |
Recruitment duration, a model prediction: none of the 24 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Oxybutinyn Vaginal Ring 4mg | Urinary Bladder, Overactive | Phase 3 | 1 |
| Oxybutinyn Vaginal Ring 6mg | Urinary Bladder, Overactive | Phase 3 | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| SCE-B | 1 |
| Synthetic Conjugated estrogens, B | 1 |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Contraception | 3 |
| Fertility and sterility | 3 |
| Chinese medical journal | 1 |
| Menopause (New York, N.Y.) | 1 |
| Obstetrics and gynecology | 1 |
Showing 5 of 6 journals.
Latest dated events (25)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2009-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2009-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2008-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2008-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2008-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 25 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BGLAP | Trial sponsor | Mentioned in trial text |
| BGLAP | Trial sponsor | Mentioned in trial text |
| SHBG | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.